Shape Security Mountain View, CA In the last year, former DOD and intelligence agency operatives have headed to Silicon Valley to create technology start-ups specializing in tools aimed at thwarting online threats. One of the start-ups is Synack, which promises to vet an army of hackers to hunt for security vulnerabilities in the computer systems of government agencies and private companies. The acquisition of the company will enable Sharklet Technologies to accelerate the development of Sharklet for medical devices where chemical-free bacterial inhibition is desired as well as high-touch surfaces prone to bacterial contamination. Sharp Edge licensed the technology from Carnegie Mellon University, and the partnership will allow the South Side-based biotech companies to develop assays used to study some cell receptors, which are of special interest to researchers.
Compared with most other Chinese VCs, however, C-Bridge is investing larger sums of capital into a relatively small portfolio. And while C-Bridge cut its teeth on more established companies, the firm is now setting its sights on building more companies from the ground up. Its two most recent investments — Everest Medicines Ltd.
Fu was previously head of principal investment at Far East Horizon. However, none of them are typical VCs raising funds from multiple LPs. Temasek is the national wealth fund of the government of Singapore, while State Development is a state-owned Chinese investment company.
Both Hillhouse and Legend are large private equity firms that invest across multiple sectors, including healthcare. C-Bridge invests about half its funds in biopharma companies, and half in medtech and service plays. Early investments included infectious disease and cancer play Ascletis BioScience Co.
Danoprevir came from Roche in a deal, when it was in Phase II testing. It is now under review in China. Ravidasvir came from Presidio Pharmaceuticals Inc.
Neither the company nor C-Bridge have disclosed precisely when the VC invested. Innovent now has three programs in Phase III testing: The company will focus on infectious diseases, renal and cardiovascular diseases, autoimmune indications and cancer, with the aim to add four to five programs every year.
Everest has operations in both the U.
In parallel with the series A round, Everest announced its first deal. Etrasimod is in Phase II testing for multiple autoimmune indications. Everest expects to announce its second deal this quarter. The company also is building an in-house small molecule drug discovery team that will focus on immuno-oncology, Cao said.
It is our way to build a global company in China. Zai has built a pipeline of five clinical candidates by licensing Chinese or global rights to cancer, autoimmune or infectious disease programs from partners such as Bristol-Myers Squibb Co.
In recent years it has increasingly focused on internal discovery and development of biologics for oncology and autoimmune disease. CMAB is using the capital to build a pilot production facility for biologics that meets global GMP standards and will initially focus on manufacturing preclinical and early clinical supplies for companies in China and worldwide.
Few Chinese contract development and manufacturing organizations CDMOs are prepared to meet global standards for quality which means there is limited capacity for domestic companies that want to file for international approvals.
Fu expects CMAB to grow rapidly. The size of the round and the participating investors have not yet been disclosed.Biotech, foreign companies, China.
Ascletis BioScience, the Hangzhou biopharma with a novel treatment for hepatitis C, may raise as much as $ million in its upcoming Hong Kong IPO, a debut offering that values the company at $2 billion.
Ascletis will be the first biotech to stage an IPO under Hong Kong's new pre-revenue IPO listing rules.
Ascletis BioScience of Beijing has signed a strategic cooperation agreement with CR Pharmaceutical Commercial Group (HK) to launch Ganovo ® (danoprevir).
Ganovo, a direct-acting anti-viral. Webcast Now Available of Press Conference Discussing Landmark Surgery Involving Harvard Bioscience's Synthetic Trachea Scaffold and "InBreath" Bioreactor PM UTC.
Ascletis BioScience of Beijing has signed a strategic cooperation agreement with CR Pharmaceutical Commercial Group (HK) to launch Ganovo ® (danoprevir). Ganovo, a direct-acting anti-viral. SHANGHAI, HANGZHOU and SHAOXING, China, Nov.
20, /PRNewswire/ -- Shanghai Roche Pharmaceuticals Ltd. (Roche) and Ascletis BioScience Co., Ltd. (Ascletis. Research and Markets: Dairy Products Market in China - Increased Demand for High Quality Foods with Bright Food, China Mengniu Dairy, Hangzhou Wahaha, Inner Mongolia Yil.